Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen-expanded DC-CIK in solid tumors
NCT05020119Phase 1Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial in solid tumor (advanced stage) (3 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoints: Acute, subacute toxicities and Adverse Events at 20 weeks, Dose-limiting toxicity at Day 28 and 1 more. Status: unknown.
02
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05020119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020119.